The table below shows ALNYLAM PHARMACEUTICALS, INC.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Revenue
$3.71B
$2.25B
$1.83B
$1.04B
$844.29M
$492.85M
Cost of revenue
$677.17M
$306.51M
$268.22M
$140.17M
$115.00M
$74.19M
Gross profit
-
-
-
-
-
-
R&D
$1.32B
$1.13B
$1.00B
$883.01M
$792.16M
$654.82M
SG&A
ALNY annual revenue (10-K history)
ALNYLAM PHARMACEUTICALS, INC. reported annual revenue of $3.71B for fiscal year 2025. That is up 65.2% from $2.25B in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $47.16M (FY 2016) to $3.71B. Figures come from the company's audited annual reports as filed with the SEC.
